Is J&J nearing the end of its opioid liability hangover?Johnson & Johnson and the ‘big three’ US pharma wholesalers are on the brink of a $26 billion Share XIs J&J nearing the end of its opioid liability hangover?https://pharmaphorum.com/news/is-jj-nearing-the-end-of-its-opioid-liability-hangover/
NIH starts trial of Pear, Chess apps for opioid use disorderPatient recruitment has begun in a National Institutes of Health (NIH) trial of two digital therapeutics (DTx) for Share XNIH starts trial of Pear, Chess apps for opioid use disorderhttps://pharmaphorum.com/news/nih-starts-trial-of-pear-chess-apps-for-opioid-use-disorder/
J&J agrees to pay $263m to settle NY opioid claims, exits marketJohnson & Johnson has shaken off another lingering liability claim in the US, agreeing a $263 million settlement Share XJ&J agrees to pay $263m to settle NY opioid claims, exits markethttps://pharmaphorum.com/news/jj-agrees-to-pay-263m-to-settle-ny-opioid-claims-exits-market/
Orexo eyes real-world testing of its modia opioid use disorder appOrexo will start a new study of its modia app – used to treat people with opioid use Share XOrexo eyes real-world testing of its modia opioid use disorder apphttps://pharmaphorum.com/news/orexo-eyes-real-world-testing-of-its-modia-opioid-use-disorder-app/
Digital therapies for opioid use disorder need more data, says ICERThere isn’t enough evidence to suggest that digital therapies for people with opioid use disorder (OUD) can improve Share XDigital therapies for opioid use disorder need more data, says ICERhttps://pharmaphorum.com/news/digital-therapies-for-opioid-use-disorder-need-more-data-says-icer/
Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
Orexo eyes opioid use disorder app launch before year-endSweden’s Orexo says its opioid use disorder (OUD) digital therapeutic – now christened Modia – is on course Share XOrexo eyes opioid use disorder app launch before year-endhttps://pharmaphorum.com/news/orexo-eyes-opioid-use-disorder-app-launch-before-year-end/
After final $600M opioid settlement, Indivior looks to the futureUK drugmaker Indivior looks finally to have put years of uncertainty over its exposure to opioid litigation in Share XAfter final $600M opioid settlement, Indivior looks to the futurehttps://pharmaphorum.com/news/after-final-600m-opioid-settlement-indivior-looks-to-the-future/
Mallinckrodt proposes $1.6bn deal to settle opioid litigationMallinckrodt is placing a $1.6 billion settlement package on the table as it tries to bring litigation related Share XMallinckrodt proposes $1.6bn deal to settle opioid litigationhttps://pharmaphorum.com/news/mallinckrodt-proposes-1-6bn-deal-to-settle-opioid-litigation/
